Summary

Eligibility
for people ages 18-99 (full criteria)
Location
at La Jolla, California
Dates
study started
estimated completion
Principal Investigator
by Rena Yadlapati, MD, MSHS
Photo of Rena Yadlapati
Rena Yadlapati

Description

Summary

This 12 week biomarker targeted double blind randomized controlled trial (RCT) will enroll subjects with salivary pepsin positive laryngopharyngeal reflux (LPR) to assess efficacy of the external upper esophageal sphincter (UES) compression device, also known as the Reflux Band. Subjects will be randomized to one of two arms: control or experimental. Following the 8 week intervention period subjects in both arms will continue in a 4 week unblinded period. The primary hypothesis is that a significantly higher proportion of subjects in the experimental arm will meet the primary endpoint for symptom response, compared to subjects in the control arm.

Official Title

Randomized Sham-Controlled Trial of the Reflux Band in Laryngopharyngeal Reflux (LPR)

Keywords

Laryngopharyngeal Reflux Proton Pump Inhibitor (PPI) Upper Esophageal Sphincter (UES) Compression Device Gastroesophageal Reflux External Upper Esophageal Sphincter (UES) Compression Device

Eligibility

You can join if…

Open to people ages 18-99

  • Adults between 18-99, English or Spanish speaking
  • ≥8 weeks of laryngeal symptoms (dysphonia, throat clearing, cough, globus, and/or sore throat)
  • Current use of double dose PPI* (equivalent to: omeprazole 40mg daily, lansoprazole 30mg daily, esomeprazole 40mg daily, dexlansoprazole 60mg daily, rabeprazole 20mg daily, or pantoprazole 80mg daily)
  • Laryngoscopic exam within 12 months prior to screening with reflux finding score >7
  • Fasting salivary pepsin concentration of ≥25 ng/mL at screening or within 4 months of enrollment

You CAN'T join if...

  • Prior use of Reflux Band (UES Compression Device)
  • Sino-pulmonary conditions (such as asthma, COPD, post-nasal drip, heavy voice use) as primary etiology of laryngeal symptoms as deemed by treating gastroenterologist and / or laryngologist
  • Laryngeal mass or lesion on laryngoscopy
  • Pregnant or breastfeeding
  • Unable to consent in English or Spanish
  • Imprisoned
  • PPI intolerance
  • Patients with a prior foregut surgery
  • Patients with a known achalasia diagnosis
  • Inability to fast for 4 hours
  • Active tobacco use
  • Supplemental oxygen use
  • Contraindication to UES Compression Device manufacturer guidelines:
  • Patients with implants or implant parts that reside in the area where Reflux Band is applied: implanted pacemarker, implanted cardioverter defibrillator (ICD), vagus nerve stimulator (VNS), or other such devices implanted in the neck
  • Patients diagnosed with glaucoma.
  • Patients who had a malignancy of the neck, including neck surgery.
  • Patients that may have an altered mental status including due to the use of sedative drugs or narcotics.
  • Patients with carotid artery disease, uncontrolled thyroid disease, a history of cerebrovascular disease, or connective tissue disorder of Marfan's Syndrome or Ehlers-Danlos Syndrome
  • Patients who use nocturnal NIV machines such as CPAP or BiPAP.

Location

  • University of California, San Diego accepting new patients
    La Jolla California 92037 United States

Lead Scientist at UCSD

  • Rena Yadlapati, MD, MSHS
    Dr. Yadlapati is medical director of the Center for Esophageal Diseases at UC San Diego Health and treats gastroesophageal reflux disease (GERD) and related conditions such as voice complaints (laryngopharyngeal reflux) and Barrett’s esophagus, swallowing disorders such as achalasia and esophageal motility disorders, and eosinophilic esophagitis.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT04827355
Study Type
Interventional
Last Updated